Proposed pathogenetic cascade of inclusion-body myositis: Importance of amyloid-β, misfolded proteins, predisposing genes, and aging

Current Opinion in Rheumatology

Volumn 15, Issue 6, 2003, Pages 737-744

  Askanas, Valerie ^a,b   Engel, W King ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Amyloid ; Misfolding of proteins; Muscle fiber aging; Sporadic inclusion body myositis

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; CAVEOLIN 1; CHOLESTEROL; CYSTATIN C; GAMMA SECRETASE; NICASTRIN; OLIGOMER; PREALBUMIN; PRESENILIN 1; PRESENILIN 2; UBIQUITIN; VALINE;

AGING; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; BIOACCUMULATION; CELL AGING; CELL CULTURE; CELL DEGENERATION; CELL VACUOLE; CLINICAL FEATURE; CYTOTOXICITY; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM; GENE DELETION; GENE FUNCTION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GERIATRIC PATIENT; HUMAN; INCLUSION BODY MYOSITIS; INTRACELLULAR SPACE; LYMPHOCYTE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE DISEASE; MUSCLE INJURY; MUTATION; OLIGOMERIZATION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SYNTHESIS; REVIEW;

AGE FACTORS; AGED; AGING; AMYLOID BETA-PROTEIN PRECURSOR; CAUSALITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUSCLE FIBERS; MYOSITIS, INCLUSION BODY; PROTEIN FOLDING; PROTEINS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0742321934     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200311000-00009     Document Type: Review

References (71)

1. Askanas V, Engel WK: Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. Curr Opin Neurol 2002, 15:525-531. Novel considerations regarding pathogenetic similarities of s-IBM and the H-IBM syndromes.
2. Askanas V, Engel WK: Newest pathogenetic considerations in inclusion-body myositis: possible role of amyloid-β, cholesterol, relation to aging and to Alzheimer's disease. Curr Rheumatol Rpts 2002, 4:427-433.
3. Mastaglia FL, Garlepp MJ, Phillips BA, et al.: Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003, 407-425. Extensive review of inflammatory myopathies.
4. Mastaglia FL, Zilko PJ: Inflammatory myopathies: how to treat the difficult cases. J Clin Neurosci 2003, 10:99-101.
5. Askanas V, Engel WK: New advances in inclusion-body myositis. Curr Opin Rheumatol 1993, 5:732-741.
6. Askanas V, Engel WK: Hereditary inclusion-body myopathies. In The Molecular and Genetic Basis of Neurologic and Psychiatric disease, edn 3. Edited by Rosenberg RN, Prusiner SB, DiMauro S, et al. Butterworth/Heineman, An Imprint of Elsevier Science: Philadelphia, 2003; pp. 501-509. Newest considerations regarding the h-IBM syndromes.
7. Askanas V, Engel WK: Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:1-14.
8. Dalakas MC: The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 2001, 1:300-306.
9. Mendell J: New insights, current concepts in the pathophysiology of inflammatory myopathies. Adv Immunother 2001, 8:12-16.
10. Dalakas MC: Understanding the immunopathogenesis of inclusion-body myositis: present and future prospects. Rev Neurol 2002, 158:948-958. Interesting review regarding immune aspects in s-IBM.
11. Wiendl H, Mitsdoerffer M, Schneider D, et al.: Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003, 126:1026-1035. Novel demonstration that muscle fibers have a machinery to serve as antigen presenting cells.
12. Jin LW, Hearn MG, Ogburn CE, et al.: Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-s myopathy similar to human inclusion body myositis. Am J Pathol 1998, 153:1679-1686.
13. Fukuchi K, Pham D, Hart M, et al.: Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998, 153:1687-1693.
14. Gallardo E, Rojas-Garcia R, de Luna N, et al.: Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001, 57:2136-2138.
15. Di Blasi C, Mora M, Pareyson D, et al.: Partial laminin α2 chain deficiency in a patient with myopathy resembling inclusion-body myositis. Ann Neurol 2000, 47:811-816.
16. Fitzsimmons RB: Facioscapulohumeral muscular dystrophy. Curr Opin Neurol 1999, 12:501-511.
17. Askanas V, McFerrin J, Baque S, et al.: Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci U S A 1996, 93:1314-1319.
18. Askanas V, McFerrin J, Alvarez RB, et al.: βAPP gene transfer into cultured human muscle induces inclusion-body myositis aspects. Neuroreport 1997, 8:2155-2158.
19. McFerrin J, Engel WK, Askanas V: Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: relevance to inclusion-body myopathies. Neuroreport 1998, 9:3201-3205.
20. Askanas V, Engel WK: Does overexpression of βAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion-body myositis, cultured human muscle and transgenic mice. Am J Pathol 1998, 153:1673-1677.
21. Gouras GK, Tsai J, Naslund J, et al.: Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 2000, 156:15-20.
22. Glabe C: Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci 2001, 17:137-145.
23. Shie F-S, LeBoeur RC, Jin L-W: Early intraneuronal Aβ deposition in the hippocampus of APP transgenic mice. Neuroreport 2003, 14:123-129.
24. Acquati F, Accarino M, Nucci C, et al.: The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the Down critical region. FEBS Lett 2000, 468:59-64.
25. Bennett BD, Babu-Khan S, Loeloff R, et al.: Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 2000, 275:20647-20651.
26. Hussain I, Powell DJ, Howlett DR, et al.: ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Mol Cell Neurosci 2000, 16:609-619.
27. Sinha S, Anderson JP, Barbour R, et al.: Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999, 402:537-540.
28. Vattemi G, Engel WK, McFerrin J, et al.: Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 2001, 358:1962-1964.
29. Vattemi G, Engel WK, McFerrin J, et al.: BACE1 and BACE2 in pathologic and normal human muscle. Exp Neurol 2003, 179:150-158. Detailed light microscopic and electron microscopic immunohistochemical and immunoblotting studies documenting the presence of BACE1 and BACE2 in normal and diseased human muscle fibers.
30. Sisodia S, St George-Hyslop PH: γ-Secretase, Notch, Aβ, and Alzheimer's disease: where do the presenilins fit in? Nature Rev 2002, 3:281-290. Very interesting review regarding AβPP processing and Alzheimer disease.
31. Ling Y, Morgan K, Kalsheker N: Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int J Biochem Cell Biol 2003, 35:1505-1535. Extensive review about AβPP processing.
32. Edbauer D, Winkler E, Regula JT, et al.: Reconstitution of gamma-secretase activity. Nat Cell Biol 2003, 5:486-488. Novel studies regarding reconstitution of the γ-secretase.
33. Li T, Ma G, Cai H, et al.: Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. J Neurosci 2003, 23:3272-3277.
34. Askanas V, Engel WK, Yang C-C, et al.: Light and electron microscopic immunolocation of Presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. Am J Pathol 1998, 152:889-895.
35. Vattemi G, Kefi M, Engel WK, et al.: Nicastrin, a novel protein participating in amyloid-β production, is overexpressed in sporadic inclusion-body myositis muscle. Neurology 2003, 60:A315.
36. Jaworska-Wilczynska M, Wilczynski GM, Engel WK, et al.: Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. Neurology 2002, 58:438-445. Important paper documenting that free cholesterol is abnormally accumulated in s-IBM muscle fibers.
37. Kefi M, Vattemi G, Engel WK, et al.: Abnormal accumulation of caveolin-1 and its colocalization with cholesterol, amyloid-β and phosphorylated tau in inclusion-body myositis (IBM) muscle. Neurology 2002, 58:A391.
38. Fielding CJ, Fielding PE: Cholesterol and caveolae: structural and functional relationships. Biochem Biophys Acta 2000, 1529:210-222.
39. McFerrin J, Engel WK, Leclerc N, et al.: Combined influence of amyloid-β precursor protein (AβPP) gene transfer and cholesterol excess on cultured normal human muscle fibers. Neurol 2002, 58:A489.
40. Deng A, Irizarry MC, Nitsch RM, et al.: Elevation of cystatin C in susceptible neurons in Alzheimer's disease. Am J Pathol 2001, 159:1061-1068.
41. Levy E, Sastre M, Kumar A, et al.: Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer-disease patients. J Neuropathol Exp Neurol 2001, 60:94-104.
42. Vattemi G, Engel WK, McFerrin J, et al.: Cystatin C colocalizes with amyloid-β and co-immunoprecipitates with amyloid-β precursor protein in sporadic inclusion-body myositis muscle. J Neurochem 2003, 85:1539-1546. Novel demonstration that cystatin C is abnormally accumulated in s-IBM muscle fibers and that it coimmunoprecipitates with AβPP.
43. Lambert MP, Barlow AK, Chromy BA, et al.: Diffusible, nonfibrillar ligands derived from Aβ 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998, 95:6448-6453.
44. Klein WL: ADDLs and protofibrils: the missing links? Neurobiol Aging 2002, 23:231-233. Very important summary stressing the significance of the Aβ oligomers and protofibrils toxicity.
45. Walsh DM, Klyubin I, Fadeeva JV, et al.: Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
46. Dahlgren KN, Manelli AM, Stine WB Jr, et al.: Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277:32046-32053.
47. Vattemi G, Checler F, Engel WK, et al.: Amyloid-β42 is preferentially deposited in muscle biopsies of patients with sporadic inclusion-body myositis (s-IBM). Neurology 2003, 60:333-334.
48. Garcia-Mata R, Gao Y-S, Sztul E: Hassles with taking out the garbage: aggravating aggresomes. Traffic 2002, 3:388-396. Excellent review regarding aggresome and unfolded proteins.
49. Sherman MY, Goldberg AL: Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29:15-32.
50. Ellis RJ, Pinheiro TJT: Danger: misfolding proteins. Nature 2002, 416:483-484.
51. Shoesmith Berke SJ, Paulson HL: Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr Opin Genet Dev 2003, 13:253-261. Excellent review regarding the contribution of the unfolded proteins in various neurodegenerative disorders.
52. Askanas V, Engel WK, Alvarez RB, et al.: Novel immunolocalization of α-synuclei in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol 2000, 59:592-598.
53. Askanas V, Bilak M, Engel WK, et al.: Prion protein is abnormally accumulated in inclusion-body myositis. Neuroreport 1993, 5:25-28.
54. Lee H-J, Lee S-J: Characterization of cytoplasmic α-synuclein aggregates. J Biol Chem 2002, 277:48976-48983. Detailed identification of α-synuclein aggregates.
55. Ma J, Wollmann R, Lindquist S: Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 2002, 298:1781-1785.
56. Namekata K, Nishimura N, Kimura H: Presenilin-binding protein forms aggresomes in monkey kidney COS-7 cells. J Neurochem 2002, 82:819-827.
57. Carriȯ MM, Villaverde A: Role of molecular chaperones in inclusion body formation. FEBS Lett 2003, 537:215-221. Good description of the importance of the molecular chaperones in inclusion body formation.
58. Ellgaard L, Helenius A: ER quality control: towards an understanding at the molecular level. Curr Opin Cell Biol 2001, 12:431-437.
59. Kaufman RJ: Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999, 13:1211-1233.
60. Lee AS: The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 2001, 26:504-510.
61. Mori K: Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 2000, 101:451-454.
62. Kaufman RJ: Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002, 110:1389-1398.
63. Vattemi G, Engel WK, Askanas V: Evidence of endoplasmic reticulum stress and unfolded protein response in inclusion-body myositis (IBM) muscle. Neurol 2002, 58:A491.
64. van Leeuwen FW, de Kleijn DP, van den Hurk HH, et al.: Frameshift mutants of β-amyloid precursor protein and ubiquitin-β in Alzheimer's and Down patients. Science 1998, 279:242-247.
65. van Leeuwen FW, Fischer DK, Kamel D, et al.: Molecular misreading: a new type of transcript mutation expressed during aging. Neurobiol Aging 2000, 21:1879-1891.
66. +1, substantially inhibits proteasomal protein degradation.
67. Fratta P, van Leeuwen FW, Engel WK, et al.: Accumulation of mutant UBB (UBB+1) in muscle fibers implicates a novel mechanism of molecular misreading in the pathogenesis of inclusion-body myositis. Neurology 2003, in press
68. Morley JF, Brignull HR, Weyers JJ, et al.: The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A 2002, 99:10417-10422.
69. Wang Y, Michikawa Y, Mallidis C, et al.: Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. Proc Natl Acad Sci U S A 2001, 98:4022-4027.
70. Askanas V, Engel WK, Alvarez RB, et al.: Inclusion-body myositis, blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele. Ann Neurol 2001, 47:544-549.
71. Askanas V, Engel WK, McFerrin J, et al.: Transthyretin Val122Ile, accumulated Aβ, and inclusion-body myositis aspects in cultured muscle. Neurol 2003, 61:257-260. First identification that mutated transthyretin promotes Aβ accumulation and IBM aspects in human muscle, providing a novel suggestion that mutated transthyretin may be a predisposing gene to IBM.